FDA Approves First Treatment for Rare Noncancerous Tumors.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Source:
    Formulary Watch. 11/28/2023, p1-1. 1p.
  • Additional Information
    • Subject Terms:
      TUMOR treatment; DISEASE progression; PAIN; UNITED States. Food & Drug Administration; ENDOWMENTS
    • Abstract:
      The article focuses on the Food and Drug Administration approval of Ogsiveo, the first treatment for rare noncancerous desmoid tumors, priced at 29,000 U.S. dollars for a 30-day supply. Topics include the drug's efficacy, impact on desmoid tumor symptoms, and its availability within five to 10 business days through specialty pharmacies after the phase 3 DeFi trial showed a 71 percent reduction in disease progression risk and common reported adverse events like diarrhea, rash, and nausea.